Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer’s Disease

  • Harald HampelEmail author
  • A. Vergallo
  • U. Bonuccelli
  • S. Lista
  • Alzheimer Precision Medicine Initiative (APMI)


  1. 1.
    O’Bryant SE, Mielke MM, Rissman RA, et al. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers. Dement. 2017;13:45–58.CrossRefPubMedGoogle Scholar
  2. 2.
    Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US) 2016.Google Scholar
  3. 3.
    Cummings J, Fox N, Vellas B, et al. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer’s Disease Task Force. J. Prev. Alzheimer’s Dis. 2018;5:103–109.Google Scholar
  4. 4.
    Hampel H, Vergallo A, Aguilar LF, et al. Precision pharmacology for Alzheimer’s disease. Pharmacol. Res. 2018;130:331–365. doi: 10.1016/j. phrs.2018.02.014.CrossRefPubMedGoogle Scholar
  5. 5.
    Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer’s disease:academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010;9:560–574.CrossRefPubMedGoogle Scholar
  6. 6.
    Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers. Dement. United States; 2013. p. 438–444.Google Scholar
  7. 7.
    Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N. Engl. J. Med. 2018;378:731–739.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hampel H, Kötter HU, Padberg F, et al. Oligoclonal bands and blood—cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. Alzheimer Dis. Assoc. Disord. 1999;13:9–19.CrossRefPubMedGoogle Scholar
  9. 9.
    Hampel H, Kötter HU, Moller HJ. Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. Alzheimer Dis. Assoc. Disord. 1997;11:78–87.CrossRefPubMedGoogle Scholar
  10. 10.
    Hampel H, Muller-Spahn F, Berger C, et al. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia. 1995;6:348–354.PubMedGoogle Scholar
  11. 11.
    Hampel H, Toschi N, Babiloni C, et al. Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. J. Alzheimers. Dis. 2018. doi: 10.3233/JAD-179932.Google Scholar
  12. 12.
    Hampel H, O’Bryant SE, Castrillo JI, et al. PRECISION MEDICINE-The Golden Gate for Detection, Treatment and Prevention of Alzheimer’s Disease. J. Prev. Alzheimer’s Dis. 2016;3:243–259.Google Scholar
  13. 13.
    Hampel H, O’Bryant SE, Durrleman S, et al. A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric. 2017;20:107–118.CrossRefPubMedGoogle Scholar
  14. 14.
    Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 2014;76:185–205.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nat. Rev. Drug Discov. England; 2013. p. 324.Google Scholar

Copyright information

© Serdi and Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Harald Hampel
    • 1
    • 2
    • 3
    • 4
    • 6
    Email author
  • A. Vergallo
    • 1
    • 2
    • 3
    • 4
  • U. Bonuccelli
    • 5
  • S. Lista
    • 1
    • 2
    • 3
    • 4
  • Alzheimer Precision Medicine Initiative (APMI)
  1. 1.AXA Research Fund & Sorbonne University ChairParisFrance
  2. 2.Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière HospitalParisFrance
  3. 3.Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225ParisFrance
  4. 4.Institute of Memory and Alzheimer’s Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HPParisFrance
  5. 5.Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
  6. 6.AXA Research Fund & Sorbonne University Chair, Sorbonne University, Department of Neurology, Institute of Memory and Alzheimer’s Disease (IM2A), Brain & Spine Institute (ICM), François Lhermitte Building, Pitié-Salpêtrière HospitalParis CEDEX 13France

Personalised recommendations